Karyopharm Therapeutics: A Critical Financial and Clinical Juncture
10.02.2026 - 10:44:03
Karyopharm Therapeutics is approaching a pivotal moment as it prepares to release its full-year 2025 financial results this Thursday. The biopharmaceutical company faces a familiar narrative of steady revenue countered by pressing liquidity concerns, with significant clinical trial data on the near-term horizon poised to influence its trajectory.
The upcoming report, scheduled for Thursday, February 12, 2026, will provide a detailed breakdown of the past year's performance. Preliminary figures indicate the company is expected to post total 2025 revenue of approximately $145 million. The cornerstone of this revenue remains the cancer drug Xpovio (selinexor), which is estimated to have generated $115 million in U.S. product sales last year. Notably, a substantial portion—around 60%—of these sales originated from community oncology practices.
Despite this revenue stability, investor attention is sharply focused on the balance sheet. As of December 31, 2025, Karyopharm held cash and equivalents of about $64 million. The company has stated that this level of liquidity is projected to fund operations only into the second quarter of 2026, underscoring the immediate need for a positive clinical or strategic catalyst.
Upcoming Catalysts: Clinical Data Readouts
The most anticipated near-term event is the release of top-line data from the Phase 3 SENTRY study in March 2026. This trial is evaluating the combination of selinexor and ruxolitinib for patients with myelofibrosis. Patient enrollment, which totaled 353 participants, was completed in September of last year, making the announced timeline likely to be met.
Should investors sell immediately? Or is it worth buying Karyopharm Therapeutics?
A second major clinical milestone is expected in mid-2026 with results from the Phase 3 XPORT-EC-042 trial in endometrial cancer. This study is testing the efficacy of selinexor as a maintenance therapy for patients with specific genetic profiles.
Executive Compensation and Holdings
Recent filings with the U.S. Securities and Exchange Commission (SEC) have shed light on executive compensation. Chief Executive Officer Richard A. Paulson was granted 81,060 restricted stock units (RSUs) on February 5. These awards are scheduled to vest in staged increments during 2027 and 2028. Following this transaction, Paulson’s direct holdings in the company amount to approximately 279,391 common shares.
As the market awaits Thursday’s earnings call, the key question is whether Karyopharm’s management can outline a credible strategy for extending its financial runway beyond the coming months. The SENTRY study data in March represents the next critical factor that will shape the market’s assessment of the company’s long-term viability and growth potential.
Ad
Karyopharm Therapeutics Stock: Buy or Sell?! New Karyopharm Therapeutics Analysis from February 10 delivers the answer:
The latest Karyopharm Therapeutics figures speak for themselves: Urgent action needed for Karyopharm Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 10.
Karyopharm Therapeutics: Buy or sell? Read more here...
